May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Effect of Topical Cyclosporine 0.05% on Enhancement Rates in Myopic LASIK Patients
Author Affiliations & Notes
  • J. P. Owen
    Ophthalmology, TLC Laser Eye Centers, Encinitas, California
  • T. Purcell
    Ophthalmology, TLC Laser Eye Centers, Encinitas, California
  • L. Cheng
    Ophthalmology, TLC Laser Eye Centers, Encinitas, California
  • D. Schanzlin
    Ophthalmology, TLC Laser Eye Centers, Encinitas, California
  • Footnotes
    Commercial Relationships  J.P. Owen, None; T. Purcell, None; L. Cheng, None; D. Schanzlin, None.
  • Footnotes
    Support  Study sponsored by unrestricted educational grant from Allergan, Inc
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 3367. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. P. Owen, T. Purcell, L. Cheng, D. Schanzlin; Effect of Topical Cyclosporine 0.05% on Enhancement Rates in Myopic LASIK Patients. Invest. Ophthalmol. Vis. Sci. 2008;49(13):3367.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To determine if the postoperative use of cyclosporine ophthalmic emulsion 0.05% (Restasis ®) reduces the enhancement rate and improves visual outcomes of myopic LASIK patients.

Methods: : A retrospective analysis was conducted on 221 myopic eyes of 126 patients who had LASIK with a single surgeon (djs). All eyes had a refractive error between plano and -6.5 dioptors with up to 2.5 dioptors of cylinder. One hundred nine eyes used topical cyclosporine twice-daily for one month as part of their post-operative protocol and 112 eyes did not use cyclosporine. All patients were treated on the VISX S4 CustomVue laser or the Allegretto excimer laser with their corneal flap created by a femtosecond laser (Intralase; Irvine, CA). Outcome variables included enhancement rates and uncorrected visual acuity (UCVA) at 1 day and 3 months postoperatively.

Results: : Eyes treated with topical cyclosporine were significantly less likely to require enhancement than eyes not treated with cyclosporine [2.8% (3/109) with cyclosporine and 9.8% (11/112) without cyclosporine (P=.031). At month 3, eyes treated with cyclosporine also had significantly better mean UCVA than eyes not treated with cyclosporine (P=.033).

Conclusions: : Postoperative topical cyclosporine ophthalmic emulsion 0.05% reduced the enhancement rate and improved visual outcomes in myopic LASIK patients.

Keywords: cyclosporine • refractive surgery: complications • refractive surgery: LASIK 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×